The assets exist.
The patients exist.
We build the switch.
A diode conducts — in one direction, with precision. That is what we do. We take science that has stalled and redirect it: to new indications, new populations, and the patients across APAC who have been waiting at the other end of the wire.
Every shelved asset is a patient who never got a chance.
Pharma pipelines hold thousands of compounds with genuine scientific potential — deprioritised not because of poor science, but because of commercial pressures, shifting strategies, and constrained R&D budgets. Diode Bio exists to find those assets and give them a forward path. We co-invest, co-develop, and carry the risk so the science can move.
The patients who need medicines most are rarely first in line.
live within the Yuxi Circle —
our home region
The Yuxi Circle — a single geographic boundary centred over East and Southeast Asia — holds more people than any comparable area on earth. Yet this region receives a fraction of global clinical trial activity relative to its scale. That gap is not a footnote. It is the opportunity.
We operate inside this circle. Through our APAC infrastructure, sovereign fund backing, and CRO partnerships, we bring medicines to populations that global pipelines have historically overlooked. Broad access here is not just a logistical advantage — it is a mandate to serve patients who have waited long enough.
The best opportunities are the ones others stopped looking for.
We are driven by a deep scientific and strategic curiosity — to look harder, look differently, and find the inflection points others walk past. Not all assets are obvious. Neither are all markets, all indications, or all partners. We combine the instincts of operators with the discipline of data to uncover opportunities that truly matter.